Siemens’ PETNET Solutions has announced a three-year agreement with The US Oncology Network to supply its entire portfolio of Food and Drug Administration (FDA)-approved positron emission tomography (PET) radiopharmaceutical agents at each of PETNET Solutions’ current Good Manufacturing Practices (cGMP)-certified locations throughout the United States.


When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.

The ASRT Foundation and RAD-AID International have announced plans to offer a program for radiation therapists to teach in China.

At the 55th American Society for Radiation Oncology (ASTRO) annual meeting, September 22-25 in Atlanta, Royal Philips featured the latest innovations that address efficient and personalized radiation oncology care for patients and their clinicians.

Accuray Inc. announced its momentum in gaining adoption for both the new CyberKnife M6 Series and TomoTherapy H Series Systems at the 55th Annual American Society for Radiation Oncology (ASTRO) Meeting taking place at the Georgia World Congress Center in Atlanta. Through presentations from leading radiation oncology practitioners and product demonstrations, attendees can gain further knowledge on the clinical capabilities of the CyberKnife M6 Series and TomoTherapy H Series Systems introduced at last year’s ASTRO meeting.

Cisplatin High-Dose Brachytherapy Beneficial for Advanced Cervical Cancer ASTRO

Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy (RT) and high-dose-rate brachytherapy (HDRB) for stage IIIB cervical cancer is beneficial, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting. The study also indicated that the combined treatments produced acceptable levels of toxicity.

iCAD Inc. has announced a strategic alliance with DermEbx to offer the Xoft Axxent Electronic Brachytherapy System to treat non-melanoma skin cancer (NMSC) throughout the DermEbx network of dermatology centers. 

Sensus Healthcare has announced its newest introduction for non-melanoma skin cancer treatment at the 55th annual American Society of Therapeutic Radiation Oncology (ASTRO) in Atlanta, Ga. Sensus has an advanced SRT-100 superficial radiotherapy platform, featuring SharpBeam and has introduced the recently FDA-cleared technology that now allows you to "See what you Treat." 

Mirada Medical has formalized an agreement with General Electric Healthcare, Milwaukee, Wis., whereby GE will license Mirada’s powerful automatic atlas-based contouring software for implementation on their AdvantageSim MD 9 virtual simulation software suite for advanced radiation therapy planning. The technology is based on Mirada Medical’s deformable registration software, which is widely regarded as best in class when aligning image data for RT planning.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now